This column is my opinion and expresses my views. Those views can change at a moments notice when the market changes. I am not right all the time and I do not expect to be. I disclose all my positions clearly listed on the page, and I do not trade my account on the stocks spoken of in this column unless fully disclosed. If that does not work for you stop reading and close the page. Do not bother me or harass me.
Otherwise, enjoy the column!
Subscribe to the Monster Stock Market Commentary to get the Weekly Monster Market Commentary and join the 3,180 subscribers getting it for FREE!
Stock Market Finds New Reasons To Drop, Plus A Quick Look At Acadia
Stock’s surged in the early going before giving back the majority of the gains. I had warned in the midday commentary to use caution, which we just saw this same story play out last week. What’s the cause, not sure. Some could point to the FBI raid of President Trump’s attorney’s office Michael Cohen, or word the Federal debt is growing larger. To be truthful, I’m not sure it even matters, because every day of the week there is a new concern and worry in the marketplace, and it continues to show us how fragile the market is. Tomorrow there will be another excuse for a sell-off.
The making of the turnaround was in works around lunchtime, with the S&P 500 stalling out around 2,650.
Micron failed miserably at resistance around $49.75.
Nvidia failed at its downtrend.
Facebook continues to fail around $161.50
Subscribe to the MCM Stock Market Commentary to get it weekly and join the 3,180 subscribers getting it for FREE!
Amazon failed again at $1440.
Microsoft failed at $93.
And last but not least, JP Morgan failed at resistance. I don’t want you to think I only write up technology stocks.
Oh, and Boeing is close to a major breakdown.
Did you see the downgrade CNN put on Acadia, yeah CNN?
Now, first I am no Dr., I have no medical experience what so ever. So this is merely my opinion based on what I have read, studied and researched on my own. So you are welcome to agree or disagree with my opinion.
If you are an investor in Acadia, as I am, you realized reasonably quickly the database the article was referring to is FAERS data. If you also thought you were having deja-vu when reading the article as well, you weren’t because this news, is nothing new. In fact, on Sept. 27, 2017, when the database first came out, the same thing happened! In fact, Acadia, Sarepta, and Ionis all trade lower, here is the article. Read the article.
I reread the transcript from the FDA panel meeting in March of 2016, and my impression is no different than it was over two years ago. The patient population is very sick and Nuplazid although not a perfect drug does offer hope to those suffering from hallucinations and delusion. The latest data from the ADP study showed that four individuals died on Placebo and 4 on Nuplazid, while 10 out of 91 on placebo had an SEA (10.99%), to Nuplazid 15 out of 90 (16.67%).
Take my opinion with a grain of salt, but those are my thoughts.
Mott Capital’s Reading The Markets – An In-depth Global Macro Stock Market Commentary – In Video Format – See How Michael Dissects The Markets
Just $200 Per Year – Get Your Free 2 Week Trial
Stock Market Rallies, Is It For Real?
What Is Going On With The Stock Market! It Is Insanity!
Where Does The Stock Market Go From Here
Free Articles Written By Mike:
Biotech’s Exact Sciences Seen Plunging 25%
Micron Options Traders Bet Stock Will Rise 14%
Disney’s Stock Seen Rising by 17%
Qualcomm Options Traders Looking for 13% Decline
Netflix Options Traders Are Looking for a Big Rebound
Why the VIX Index Is a Bullish Sign for Stocks
Apple Stock Faces 10% Short-Term Pullback
4 Consumer Stocks That May Plunge to New Lows
Broadcom’s Battered Stock Poised for 12% Rebound
Boeing’s Stock Seen Falling Into Bear Market
IBM Traders See Stock Plunging 20%
3 Hot Biotech Stocks Facing Sharp Declines
Under Armour’s Stock Still Has Further to Fall
Intel Traders Face Big Losses As Chipmaker’s Stock Drops
Why Facebook Stock May Rebound By 25%
Amazon’s Stock May Plunge 10% Further
Tech Stocks’ Growth Engine Faces a Big Slowdown
3 Big Biotech Stocks Poised for More Declines
Why Chip Stocks May Rebound to Record Highs
Take-Two Stock Seen Rising 20% on E-Sports Demand
Square’s Soaring Stock Is Due for a Correction
Nike’s Stock Bulls May Get Burned
Why AMD Options Traders Are Bearish Long Term
Improving Earnings Will Push Stock Prices Higher
Join our 3,180 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe
[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”]
Michael Kramer and Clients of Mott capital own shares of ACAD
Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.
© 2018 Mott Capital Management, LLC. Use, publication or reproduction in any media prohibited without the permission of the copyright holder.
Tags: #stockmarket #april9 #monday #trading